Semaglutide Drug

## What it is Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a synthetic peptide modified from native human GLP-1 with two key structural changes: an alanine-to-aminoisobutyric acid substitution at position 8 to resist DPP-4 degradation, and a fatty acid side chain at lysine 26 that promotes albumin binding and extends the plasma half-life from minutes (native GLP-1) to roughly 7 days. Together these modifications make once-weekly subcutaneous dosing feasible. The regulatory history is a story of expanding indications. Ozempic (subcutaneous semaglutide for type 2 diabetes) received FDA approval in December 2017. Rybelsus (oral semaglutide for type 2 diabetes) followed in September 2019. Wegovy (subcutaneous semaglutide at 2.4 mg weekly for chronic weight management) received approval in June 2021 based on the STEP trial program. The SELECT trial (2023) extended the indication to cardiovascular event reduction in adults with established cardiovascular disease and overweight or obesity without type 2 diabetes. The compound has become a defining cultural and economic phenomenon since 2022. The Ozempic and Wegovy supply could not meet demand from 2022 through 2024, and the FDA's official shortage designation enabled compounding pharmacies (503A and 503B) to legally produce semaglutide outside Novo Nordisk's supply chain. The shortage list designation was removed in February 2025, narrowing the legal compounding window substantially. Today there are three distinct user populations: insurance-covered patients receiving branded Ozempic for diabetes or Wegovy for obesity, cash-paying patients receiving compounded semaglutide through telehealth services, and a smaller population using grey-market product purchased through international suppliers. ## Mechanism of action GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. It potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion from alpha cells, slows gastric emptying, and acts on hypothalamic and brainstem circuits to promote satiety. Native GLP-1 is degraded within minutes by the enzyme DPP-4. Semaglutide's structural modifications make it resistant to DPP-4 and bind it to albumin, extending the functional half-life to roughly 168 hours. The glucose-dependent nature of the insulinotropic effect is clinically important: GLP-1 agonists do not produce hypoglycemia in monotherapy because the insulin-secreting effect is gated by elevated blood glucose. Hypoglycemia risk emerges only when GLP-1 agonists are combined with insulin or sulfonylureas, in which case the existing agent's dose typically requires reduction. The satiety mechanism is the dominant driver of the weight-loss effect. GLP-1 receptors are expressed in the arcuate nucleus of the hypothalamus and the area postrema in the brainstem, both of which are central to appetite regulation. Functional MRI studies show reduced reward-related activation to food cues during semaglutide treatment, alongside slower gastric emptying that prolongs the postprandial 'full' signal. The result is a substantial reduction in caloric intake, with most patients describing the experience as 'food noise' fading rather than as forced restriction. The cardiovascular benefit observed in SELECT and SUSTAIN-6 likely combines several mechanisms: weight loss, improved glycemic control, modest blood-pressure reduction, anti-inflammatory effects on vascular endothelium, and possibly direct effects on atherosclerotic plaque. The relative contribution of each is unsettled. ## Evidence base by outcome ### Weight loss in obesity without diabetes The STEP-1 trial (n=1,961 adults with obesity, 68 weeks, semaglutide 2.4 mg weekly versus placebo) reported mean body-weight loss of 14.9% versus 2.4% on placebo. STEP-3 added intensive behavioral therapy and reported similar magnitude. STEP-4 examined withdrawal effects: participants who reached the maximum dose at week 20 and then continued or switched to placebo for 48 weeks regained roughly two-thirds of lost weight in the placebo arm versus continued weight loss in the semaglutide arm. The withdrawal pattern is consistent with the hormone-replacement framing: stopping the medication reverses the appetite signal. ### Weight loss in type 2 diabetes The SUSTAIN program covered semaglutide in T2DM at doses of 0.5 and 1.0 mg weekly. SUSTAIN-1 through SUSTAIN-7 reported mean weight reductions of 4 to 7 kg over 30 to 56 weeks at 1 mg weekly. Effects in T2DM are smaller than in non-diabetic obesity at equivalent doses, a pattern observed across the GLP-1 class. ### HbA1c reduction Across the SUSTAIN trials, semaglutide 1.0 mg weekly reduced HbA1c by 1.4 to 1.8 percentage points versus placebo or active comparators. Head-to-head against sitagliptin (SUSTAIN-2), exenatide ER (SUSTAIN-3), insulin glargine (SUSTAIN-4), and dulaglutide (SUSTAIN-7), semaglutide produced superior HbA1c reductions. SURPASS-2 then showed tirzepatide superior to semaglutide 1.0 mg, displacing semaglutide from the top of the class on glycemic endpoints. ### Cardiovascular outcomes SUSTAIN-6 (n=3,297 T2DM patients with high CV risk, 2 years) reported a 26% reduction in the composite of CV death, non-fatal MI, and non-fatal stroke versus placebo. SELECT (n=17,604 adults with overweight or obesity and established CVD but without diabetes) reported a 20% reduction in major adverse cardiovascular events over a mean 33 months. The SELECT result is the most clinically transformative finding in the program: it established that GLP-1 agonism produces hard cardiovascular benefit even in the absence of diabetes. ### Body composition and lean-mass loss Body-composition substudies report that 30 to 40% of the total mass lost on semaglutide monotherapy is lean tissue. The pattern is similar to other forms of substantial caloric restriction without resistance training. Resistance training plus elevated protein intake (1.6 to 2.2 g/kg/day) attenuates the lean-mass loss meaningfully. The trial evidence on this attenuation comes from observational and small interventional studies rather than dedicated RCTs, but the principle is well-established in the broader weight-loss literature. ### Other endpoints Gallbladder disease incidence is roughly doubled relative to placebo, consistent with the broader pattern of rapid weight loss. Pancreatitis signal is contested; the absolute risk is small and the relative risk is unclear. Suicidality and mood signals from post-marketing surveillance have been reviewed by FDA and EMA without finding a clear elevation. Renoprotective signals in T2DM with CKD risk are present but small. Resting metabolic rate decreases modestly during the weight-loss phase, which is expected with any substantial weight reduction. ## Dosage and titration The Wegovy titration schedule for chronic weight management is the canonical protocol: 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then 2.4 mg weekly maintenance. The slow ramp is explicitly designed to manage GI tolerability rather than to reach therapeutic effect; the appetite suppression at 0.25 mg is meaningfully lower than at 2.4 mg, but the intermediate steps are about preventing the GI side effects that drive discontinuation. The Ozempic titration for T2DM follows a similar but compressed schedule, typically reaching 1.0 mg weekly as the standard maintenance dose. The 2.0 mg dose was approved in 2022 and provides additional glycemic and weight benefit at increased GI cost. Oral semaglutide (Rybelsus) is dosed daily on an empty stomach with a small amount of water, with no food or other medications for at least 30 minutes after dosing. The bioavailability is roughly 1% and is highly sensitive to the fasting window. The convenience advantage is real for patients averse to injection; the practical compliance burden is non-trivial. No cycling is part of the protocol. Semaglutide is titrated up over months and continued indefinitely while clinically appropriate. Discontinuation typically results in regain of roughly two-thirds of lost weight over the following year, as STEP-4 documented. Dose adjustments down are appropriate when GI side effects become intolerable. Many patients land at 1.7 mg or 1.0 mg as a steady state rather than the maximum 2.4 mg. The dose-response is meaningful but not enormous between 1.7 and 2.4 mg, and the tolerability gain is often worth it. ## Side effects and safety GI effects dominate the adverse-event profile. Across STEP and SUSTAIN trials: nausea (around 40 to 45% at 2.4 mg, 15 to 20% at 1.0 mg), diarrhea (25 to 30%), vomiting (15 to 25%), and constipation (15 to 25%). These cluster around dose escalations and ease with slow titration. Overall discontinuation for GI reasons in STEP-1 was around 7%. Gallbladder events (cholelithiasis, cholecystitis) occur at roughly twice the placebo rate, consistent with rapid weight loss in any context. Pancreatitis is a labeled warning; the absolute risk is small (around 0.1 to 0.2% over 1 to 2 years) and the relative risk versus placebo is contested in meta-analyses. The medullary thyroid carcinoma warning derives from rodent data showing C-cell tumors with chronic high-dose GLP-1 agonism. The human relevance is uncertain but the FDA boxed warning persists. Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome is a hard contraindication. Lean-mass loss is real and meaningful in users not pairing with resistance training and adequate protein. The functional consequence (sarcopenia, reduced metabolic rate, increased frailty in older users) is the strongest argument for treating semaglutide as one component of a metabolic protocol rather than as a standalone weight intervention. Drug interactions are largely mediated by delayed gastric emptying. Insulin and sulfonylureas typically need dose reduction to prevent hypoglycemia. Oral medications (warfarin, oral contraceptives, levothyroxine) may have altered absorption kinetics that warrant monitoring. The interaction profile is otherwise modest. Pregnancy is a contraindication. The label recommends discontinuation 2 months before planned pregnancy due to the long half-life. Lactation use is similarly not recommended. ## Stack interactions and timing The most important pairing is with structured resistance training and adequate protein intake. This is not a stacking nicety; it is the difference between sustainable weight loss with preserved function and a clinical trajectory toward sarcopenia. 1.6 to 2.2 g/kg/day protein, distributed across 3 to 4 meals, is the standard prescription. Two to three resistance training sessions per week is the minimum. Creatine monohydrate at 3 to 5 g/day is a sensible adjunct for users prioritizing lean-mass preservation. The mechanism (improved training capacity and recovery) supports the resistance-training prescription rather than directly counteracting GLP-1 effects. Pairing with metformin is common in T2DM and is generally well-tolerated, with additive glycemic benefit and modest additive weight effects. Pairing with SGLT2 inhibitors similarly produces additive benefit. Injection timing within the week is flexible. Once-weekly dosing on a fixed day is standard. The injection rotates between abdomen, thigh, and upper arm. Branded pens (Ozempic, Wegovy) ship pre-filled. Compounded vials require reconstitution and drawing the dose on a U100 insulin syringe. ## Practical notes Branded pens are stored refrigerated (2 to 8 degrees C) until first use, after which they can sit at room temperature for up to 56 days for Ozempic or 28 days for Wegovy. Compounded semaglutide is typically supplied as lyophilized powder reconstituted with bacteriostatic water and refrigerated; sterility and stability vary by pharmacy. Expect satiety changes within the first week of even the starter 0.25 mg dose. The largest weight changes accumulate over months, with the STEP-1 weight curve still trending down at week 68. Plan for GI side effects to peak after each escalation and resolve within 1 to 2 weeks. The honest framing for users considering semaglutide: this is a chronic medication with a powerful effect on appetite and a meaningful side-effect profile. Discontinuation almost always produces regain. Anyone treating it as a short-term weight-loss tool is misunderstanding the pharmacology. Combined with resistance training, adequate protein, and ongoing clinical follow-up, it is one of the most effective metabolic interventions in modern medicine. Used in isolation, it produces weight loss with substantial lean-mass cost and high regain on discontinuation.